content: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
         Date of Report (Date of earliest event reported): February 16, 2000
  
  
                                 IMMUNOMEDICS, INC.
               (Exact name of registrant as specified in its charter)
  
  
           Delaware              0-12104              61-1009366
      (State or Other         Jurisdiction        (Commission (IRS Employer
      of Incorporation)       File Number)        Identification No.)
  
                 300 American Road, Morris Plains, New Jersey 07950
                 (Address of principal executive offices) (Zip Code)
  
         Registrant's telephone number, including area code: (973) 605-8200
  
            (Former name or former address, if changed since last report)
  
  <PAGE>
  
  Item 5.  Other Events
  
            On February 16, 2000, the registrant  completed a private placement of
  2.325  million  shares of its Common Stock for a total  purchase  price of $37.2
  million. The shares were not registered under the Securities Act of 1933 and may
  not be offered or sold in the United States absent registration or an applicable
  exemption from registration requirements.  The registrant is obligated to file a
  registration  statement with the Securities and Exchange Commission covering the
  resale of such shares.
  
  Item 7.  Financial Statements and Exhibits
  
           Exhibit 99.1     Press Release dated February 17, 2000
  
                                        -2-
  
  <PAGE>
  
                                     SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned thereunto duly authorized.
  
                                                      IMMUNOMEDICS, INC.
  
  
                                                       By: /s/ David M. Goldenberg
                                                       ---------------------------
                                                         David M. Goldenberg,
                                                         Chairman of the Board and
                                                         Chief Executive Officer
  
  Date:  February 23, 2000
  
                                        -3-
  
  <PAGE>
  
                                    EXHIBIT INDEX
  
  Exhibit 99.1       Press Release dated February 17, 2000
  
  
  
  
  
  
  
  
  
                                        -4-
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "8-K", "secsgml_size_bytes": 2642}]
metadata_filer: {"company-data": {"conformed-name": "IMMUNOMEDICS INC", "cik": "0000722830", "assigned-sic": "2835", "irs-number": "611009366", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12104", "film-number": "551403"}, "business-address": {"street1": "300 AMERICAN RD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950", "phone": "9736058200"}, "mail-address": {"street1": "300 AMERICAN ROAD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
         Date of Report (Date of earliest event reported): February 16, 2000
  
                                 IMMUNOMEDICS, INC.
               (Exact name of registrant as specified in its charter)
  
           Delaware              0-12104              61-1009366
      (State or Other         Jurisdiction        (Commission (IRS Employer
      of Incorporation)       File Number)        Identification No.)
  
                 300 American Road, Morris Plains, New Jersey 07950
                 (Address of principal executive offices) (Zip Code)
  
         Registrant's telephone number, including area code: (973) 605-8200
  
            (Former name or former address, if changed since last report)
  Item 5.  Other Events
  
            On February 16, 2000, the registrant  completed a private placement of
  2.325  million  shares of its Common Stock for a total  purchase  price of $37.2
  million. The shares were not registered under the Securities Act of 1933 and may
  not be offered or sold in the United States absent registration or an applicable
  exemption from registration requirements.  The registrant is obligated to file a
  registration  statement with the Securities and Exchange Commission covering the
  resale of such shares.
  
  Item 7.  Financial Statements and Exhibits
  
           Exhibit 99.1     Press Release dated February 17, 2000
  
                                        -2-
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned thereunto duly authorized.
  
                                                      IMMUNOMEDICS, INC.
  
                                                       By: /s/ David M. Goldenberg
                                                       ---------------------------
                                                         David M. Goldenberg,
                                                         Chairman of the Board and
                                                         Chief Executive Officer
  
  Date:  February 23, 2000
  
                                        -3-
  EXHIBIT INDEX
  
  Exhibit 99.1       Press Release dated February 17, 2000
  
                                        -4-